Global epinephrine market projected to reach $5.53b by 2032

The APAC market is poised to lead amidst its expanding population and healthcare spending.

The global market for epinephrine is anticipated to reach $5.53b by 2032 at a compound annual growth rate (CAGR) of 11.4%, according to Adroit Market Research.

The report revealed that the market is experiencing significant growth due to the rising prevalence of life-threatening allergic reactions, particularly anaphylaxis.

“Epinephrine, also recognised as adrenaline, serves as a vital hormone and neurotransmitter that aids in the relaxation of airway muscles, constriction of blood vessels, and elevation of heart rate,” The report said.

Meanwhile, the Asia Pacific (APAC) region is expected to lead the global market due to factors such as an expanding population, growth in healthcare spending, and an increasing awareness concerning allergy-related disorders.

Moreover, the presence of pharmaceutical firms dedicated to the innovation and provision of epinephrine items is set to further drive the region’s market.

Furthermore, auto-injectors are projected to witness a surge in demand amongst other products in the market amidst the increasing preference for self-administered therapies.

“These devices are specifically engineered to deliver a precise dosage of epinephrine rapidly and effectively, making them well-suited for urgent situations,” The report added.

It also stated that technological advancements related to auto-injectors are enhancing the ease of self-administration, which further contributes to a boost in market demand and expansion.